Testing effectiveness (Phase 2)Active Not RecruitingNCT05787613
What this trial is testing
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
Who this might be right for
NSCLC Stage IV
Shanghai Henlius Biotech 132